These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25726326)

  • 21. Guide for medical professionals (i.e., dermatologists) for the management of Rhododenol-induced leukoderma.
    Nishigori C; Aoyama Y; Ito A; Suzuki K; Suzuki T; Tanemura A; Ito M; Katayama I; Oiso N; Kagohashi Y; Sugiura S; Fukai K; Funasaka Y; Yamashita T; Matsunaga K
    J Dermatol; 2015 Feb; 42(2):113-28. PubMed ID: 25622988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and epidemiological analysis in 149 cases of rhododendrol-induced leukoderma.
    Yoshikawa M; Sumikawa Y; Hida T; Kamiya T; Kase K; Ishii-Osai Y; Kato J; Kan Y; Kamiya S; Sato Y; Yamashita T
    J Dermatol; 2017 May; 44(5):582-587. PubMed ID: 27882588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of rhododendrol and its metabolic products on melanocytic cell growth.
    Okura M; Yamashita T; Ishii-Osai Y; Yoshikawa M; Sumikawa Y; Wakamatsu K; Ito S
    J Dermatol Sci; 2015 Nov; 80(2):142-9. PubMed ID: 26282085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human tyrosinase is able to oxidize both enantiomers of rhododendrol.
    Ito S; Gerwat W; Kolbe L; Yamashita T; Ojika M; Wakamatsu K
    Pigment Cell Melanoma Res; 2014 Nov; 27(6):1149-53. PubMed ID: 25130058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Leukoderma induced by rhododendrol is different from leukoderma of vitiligo in pathogenesis: A novel comparative morphological study.
    Tsutsumi R; Sugita K; Abe Y; Hozumi Y; Suzuki T; Yamada N; Yoshida Y; Yamamoto O
    J Cutan Pathol; 2019 Feb; 46(2):123-129. PubMed ID: 30456919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autoantibodies detected in patients with vitiligo vulgaris but not in those with rhododendrol-induced leukoderma.
    Arase N; Tanemura A; Jin H; Nishioka M; Aoyama Y; Oiso N; Matsunaga K; Suzuki T; Nishigori C; Kawamura T; Shimizu T; Ito A; Fukai K; Abe Y; Yang L; Tsuruta D; Takeoka K; Iwatani Y; Hidaka Y; Nishida M; Yamauchi-Takihara K; Arase H; Fujimoto M; Katayama I
    J Dermatol Sci; 2019 Aug; 95(2):80-83. PubMed ID: 31399283
    [No Abstract]   [Full Text] [Related]  

  • 27. 4-(4-Hydroxyphenyl)-2-butanol (rhododendrol)-induced melanocyte cytotoxicity is enhanced by UVB exposure through generation of oxidative stress.
    Goto N; Tsujimoto M; Nagai H; Masaki T; Ito S; Wakamatsu K; Nishigori C
    Exp Dermatol; 2018 Jul; 27(7):754-762. PubMed ID: 29630780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The spectrophotometrical analysis of rhododendrol-induced leucoderma using a novel multispectral camera.
    Inoue M; Kikuchi K; Watabe A; Yamasaki K; Aiba S
    Br J Dermatol; 2016 Aug; 175(2):334-9. PubMed ID: 26991967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term Use of Topical Bimatoprost on Rhododendrol-induced Refractory Leukoderma: A Case Report.
    Fukaya S; Kamata M; Kasanuki T; Yokobori M; Takeoka S; Hayashi K; Tanaka T; Fukuyasu A; Ishikawa T; Ohnishi T; Iimuro S; Watanabe S; Tada Y
    Acta Derm Venereol; 2019 Nov; 99(12):1178-1179. PubMed ID: 31449314
    [No Abstract]   [Full Text] [Related]  

  • 30. The effect of rhododendrol inhibition of NF-κB on melanocytes in the presence of tyrosinase.
    Arase N; Yang L; Tanemura A; Yang F; Suenaga T; Arase H; Katayama I
    J Dermatol Sci; 2016 Aug; 83(2):157-9. PubMed ID: 27174091
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunohistochemical analysis of rhododendrol-induced leukoderma in improved and aggravated cases.
    Yasuda M; Sekiguchi A; Kishi C; Toki S; Arase N; Takahashi A; Yang F; Tanemura A; Hayashi M; Abe Y; Hamada T; Suzuki T; Katayama I; Ishikawa O
    J Dermatol Sci; 2020 Aug; 99(2):140-143. PubMed ID: 32653297
    [No Abstract]   [Full Text] [Related]  

  • 32. Genome-wide association study identifies CDH13 as a susceptibility gene for rhododendrol-induced leukoderma.
    Okamura K; Abe Y; Naka I; Ohashi J; Yagami A; Matsunaga K; Kobayashi Y; Fukai K; Tanemura A; Katayama I; Masui Y; Ito A; Yamashita T; Nagai H; Nishigori C; Oiso N; Aoyama Y; Araki Y; Saito T; Hayashi M; Hozumi Y; Suzuki T
    Pigment Cell Melanoma Res; 2020 Nov; 33(6):826-833. PubMed ID: 32558222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rhododendrol-induced leukoderma accompanied by allergic contact dermatitis caused by a non-rhododendrol skin-lightening agent, 5,5'-dipropylbiphenyl-2,2'-diol.
    Yagami A; Suzuki K; Sano A; Takahashi M; Kobayashi T; Morita Y; Ando A; Iwata Y; Matsunaga K
    J Dermatol; 2015 Jul; 42(7):739-40. PubMed ID: 25875673
    [No Abstract]   [Full Text] [Related]  

  • 34. The mechanism of melanocytes-specific cytotoxicity induced by phenol compounds having a prooxidant effect, relating to the appearance of leukoderma.
    Nagata T; Ito S; Itoga K; Kanazawa H; Masaki H
    Biomed Res Int; 2015; 2015():479798. PubMed ID: 25861631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A cell-based evaluation of human tyrosinase-mediated metabolic activation of leukoderma-inducing phenolic compounds.
    Nishimaki-Mogami T; Ito S; Cui H; Akiyama T; Tamehiro N; Adachi R; Wakamatsu K; Ikarashi Y; Kondo K
    J Dermatol Sci; 2022 Nov; 108(2):77-86. PubMed ID: 36567223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A convenient screening method to differentiate phenolic skin whitening tyrosinase inhibitors from leukoderma-inducing phenols.
    Ito S; Wakamatsu K
    J Dermatol Sci; 2015 Oct; 80(1):18-24. PubMed ID: 26228294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rhododendrol-induced leukoderma update I: Clinical findings and treatment.
    Matsunaga K; Suzuki K; Ito A; Tanemura A; Abe Y; Suzuki T; Yoshikawa M; Sumikawa Y; Yagami A; Masui Y; Inoue S; Ito S; Katayama I
    J Dermatol; 2021 Jul; 48(7):961-968. PubMed ID: 33686651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tyrosinase-Catalyzed Oxidation of the Leukoderma-Inducing Agent Raspberry Ketone Produces (E)-4-(3-Oxo-1-butenyl)-1,2-benzoquinone: Implications for Melanocyte Toxicity.
    Ito S; Hinoshita M; Suzuki E; Ojika M; Wakamatsu K
    Chem Res Toxicol; 2017 Mar; 30(3):859-868. PubMed ID: 28219012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A framework to mitigate the risk of chemical leukoderma: Consumer products.
    Bjerke DL; Wu S; Wakamatsu K; Ito S; Wang J; Laughlin T; Hakozaki T
    Regul Toxicol Pharmacol; 2022 Jun; 131():105157. PubMed ID: 35292310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progression from in vivo validation to in vitro screening in hazard assessment for leukoderma-inducible chemicals.
    Tazaki A; Nishadhi DASM; Li A; Zhang L; Maw TH; Kondo-Ida L; Yanagisawa K; Kato M
    Environ Pollut; 2024 Sep; 356():124508. PubMed ID: 39089942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.